Adjuvant endocrine therapy for breast cancer: a commentary.

摘要

One area that some might see differently is the role of ovarian ablation in the adjuvant treatment of premenopausal women. The original Early Breast Cancer Tfialists' Collaborative Group (EBCTCG) overview showed that ovarian ablation, mainly surgical or radiation-based in those days, improved disease-free survival and overall survival even in a setting in which patients had not been selected (on the basis of estrogen receptor [ER] status) to be hormonally sensitive. [1,2] The current use of tamoxifen as the standard—and its inclusion as the standard in the National Comprehensive Cancer Network (NCCN),[3] American Society of Clinical Oncology (ASCO),[4]